EXPERIENCE WITH TRILOSTANE IN THE TREATMENT OF CUSHING'S SYNDROME |
| |
| Authors: | P. DEWIS D. C. ANDERSON DENISE E. BU'LOCK ROSEMARY EARNSHAW W. F. KELLY |
| |
| Affiliation: | Departments of Medicine and Chemical Pathology, Hope Hospital (University of Manchester School of Medicine), Eccles Old Road, Salford M6 8HD and Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester |
| |
| Abstract: | ![]()
Five patients with pituitary dependent Cushing's syndrome and two with adrenal carcinoma were treated with increasing doses of trilostane (up to 1440 mg daily). There was no consistent fall in serum cortisol levels. In addition there was no rise in the levels of precursors immediately preceding the proposed site of action of trilostane. These results suggest that trilostane does not effectively block the enzyme 3β-hydroxysteroid dehydrogenase Δ4,Δ5 isomerase in patients with Cushing's syndrome and that it should no longer be recommended for their treatment. |
| |
| Keywords: | |
|
|
